Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...
Hosted on MSN1mon
Gyre Therapeutics president Ma Songjiang sells $42,760 in stockSAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company currently valued at $968 million, recently sold a total of 4,000 shares of the company's ...
Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $12.43. Gyre Therapeutics shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback